Chr t(11;14)

News alerts, weekly reports and conference planners

Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	venetoclax + bortezomib Sensitive: B - Late Trials venetoclax + bortezomib Sensitive : B	venetoclax + bortezomib Sensitive: B - Late Trials venetoclax + bortezomib Sensitive : B
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	Resistant: B - Late Trials Resistant : B	Resistant: B - Late Trials Resistant : B
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	Resistant: B - Late Trials Resistant : B	Resistant: B - Late Trials Resistant : B
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2	venetoclax Sensitive: C2 – Inclusion Criteria venetoclax Sensitive : C2
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	venetoclax + atezolizumab + cobimetinib Sensitive: C2 – Inclusion Criteria venetoclax + atezolizumab + cobimetinib Sensitive : C2	venetoclax + atezolizumab + cobimetinib Sensitive: C2 – Inclusion Criteria venetoclax + atezolizumab + cobimetinib Sensitive : C2
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	Resistant: C3 – Early Trials Resistant : C3	Resistant: C3 – Early Trials Resistant : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	bortezomib Sensitive: C3 – Early Trials bortezomib Sensitive : C3	bortezomib Sensitive: C3 – Early Trials bortezomib Sensitive : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	MEK inhibitor + BRAF inhibitor Sensitive: C3 – Early Trials MEK inhibitor + BRAF inhibitor Sensitive : C3	MEK inhibitor + BRAF inhibitor Sensitive: C3 – Early Trials MEK inhibitor + BRAF inhibitor Sensitive : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	BRAF inhibitor Sensitive: C3 – Early Trials BRAF inhibitor Sensitive : C3	BRAF inhibitor Sensitive: C3 – Early Trials BRAF inhibitor Sensitive : C3
Chr t(11;14)	Multiple Myeloma	Chr t(11;14)	Multiple Myeloma	venetoclax + cobimetinib Sensitive: C3 – Early Trials venetoclax + cobimetinib Sensitive : C3	venetoclax + cobimetinib Sensitive: C3 – Early Trials venetoclax + cobimetinib Sensitive : C3

Chr t(11;14)

Associations